GSK’s HIV Unit, ViiV Healthcare, Helping Spur Growth In Company

Financial Times: HIV unit emerges as ‘critical’ driver of GSK growth
“It is only a year since GlaxoSmithKline was considering a spin-off of its HIV unit as a way to unlock value for disgruntled shareholders. The option was rejected and now the business, known as ViiV Healthcare, is playing an increasingly important role in efforts to return the U.K. drugmaker to growth…” (Ward, 2/25).